Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia

Circulation

Volumn 103, Issue 14, 2001, Pages 1838-1843

  Lewis, B E ^a   Wallis, D E ^b   Berkowitz, S D ^c,n   Matthai, W H ^d   Fareed, J ^a   Walenga, J M ^a   Bartholomew, J ^e,n   Sham, R ^f,n   Lerner, R G ^g   Zeigler, Z R ^h   Rustagi, P K ⁱ   Jang, I K ^j,n   Rifkin, S D ^k   Moran, J ^a,n   Hursting, M J ^l   Kelton, J G ^m   Ahn, Y ⁿ   Akers, D ⁿ   Alving, B ⁿ   Andes, W ⁿ   Arabia, F ⁿ   Ayala, K ⁿ   Azar, H ⁿ   Barton, J ⁿ   Baynes, R ⁿ   Bengston, J ⁿ   Berkman, S ⁿ   Bhanja, U ⁿ   Bianco, A ⁿ   Blaszkowsky, L ⁿ   Bona, R ⁿ   Boxer, M ⁿ   Brown, A ⁿ   Chang, J ⁿ   Chediak, J ⁿ   Cochran, D ⁿ   Cohen, A ⁿ   Cohen, M ⁿ   Cushman, M ⁿ   Diuguid, D ⁿ   Eby, C ⁿ   Elliot, G ⁿ   Faig, D ⁿ   Francis, C ⁿ   Francis, J ⁿ   Fried, W ⁿ   Gabriel, D ⁿ   Gernsheimer, T ⁿ   Greeno, E ⁿ   Hack, T ⁿ   Haire, W ⁿ   Hassell, K ⁿ   Hild, D ⁿ   Horne, M ⁿ   Hutchins, M ⁿ   Irani, M ⁿ   Jubelirer, S ⁿ   Juckett, M ⁿ   Kessler, C ⁿ   Khan, A ⁿ   Konkle, B ⁿ   Lerner, R ⁿ   Levitt, L ⁿ   Leya, F ⁿ   Luterman, A ⁿ   Lyons, R ⁿ   MacFarlane, D ⁿ   Makary, A ⁿ   Matthai, W ⁿ   McClurken, J ⁿ   McGehee, W ⁿ   McKenna, R ⁿ   Mena, R ⁿ   Ortega, G ⁿ   Paulson, R ⁿ   Penner, J ⁿ   Perry, J ⁿ   Reeves, J ⁿ   Rehman, K ⁿ   Rice, L ⁿ   Richman, E ⁿ   Rifkin, S ⁿ   Rubin, J ⁿ   Rustagi, P ⁿ   Santiago, M ⁿ   Schacht, N ⁿ   Schmaier, A ⁿ   Shopnick, R ⁿ   Shuman, M ⁿ   Shurafa, M ⁿ   Siegel, J ⁿ   Sobel, M ⁿ   Soff, G ⁿ   Staszewski, H ⁿ   Strony, J ⁿ   Telfer, M ⁿ   Trowbridge, A ⁿ   Wallis, D ⁿ   Warr, T ⁿ   Williams, E ⁿ   Wiseman, A ⁿ   Zehnder, J ⁿ   Zeigler, Z ⁿ   Zimmerman, M ⁿ   more..

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b Midwest Heart Specialists   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f ROCHESTER GENERAL HOSPITAL   (United States)

^g WESTCHESTER MEDICAL CENTER   (United States)

^h WESTERN PENNSYLVANIA HOSPITAL   (United States)

ⁱ UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^j MASSACHUSETTS GENERAL HOSPITAL   (United States)

^k Texas Biotechnology Corporation   (United States)

^l TEXAS BIOTECHNOLOGY CORPORATION   (United States)

^m MCMASTER UNIVERSITY   (Canada)

ⁿ NONE

more..

Author keywords

Anticoagulants; Heparin; Inhibitors; Platelets; Thrombosis

Indexed keywords

ANCROD; ARGATROBAN; DANAPAROID; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT HIRUDIN; THROMBIN INHIBITOR; WARFARIN;

ADULT; AGED; AMPUTATION; ANTICOAGULATION; ARTICLE; BLEEDING; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; IMMUNE MEDIATED INJURY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME;

EID: 0035836541     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.103.14.1838     Document Type: Article

References (25)

1. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101:502-507.
2. Brieger DB, Mak K-H, Kottke-Marchant K, et al. Heparin-induced thrombocytopenia. J Am Coll Cardiol. 1998;31:1449-1459.
3. Nand S, Wong W, Yuen B, et al. Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol. 1997;56:12-16.
4. Greinacher A, Volpel H, Janssens U, et al, for the HIT investigators group. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation. 1999;99:73-80.
5. Horsewood P, Warkentin TE, Hayward CPM, et al. The epitope specificity of heparin-induced thrombocytopenia. Br J Haematol. 1996;95: 161-167.
6. Chong BH, Fawaz I, Chesterman CN, et al. Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets. Br J Haematol. 1989;73:235-240.
7. Warkentin TE, Hayward CPM, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood. 1994;84: 3691-3699.
8. Boshkov LK, Warkentin TE, Haywood CPM, et al. Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Haematol. 1993;84:322-328.
9. Wallis DE, Workman DL, Lewis BE, et al. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med. 1999;106:629 - 635.
10. King D, Kelton JG. Heparin-induced thrombocytopenia. Ann Intern Med. 1984;100:535-540.
11. Demers C, Ginsberg JS, Brill-Edwards P, et al. Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia. Blood. 1991;78: 2194-2197.
12. Leroy J, Leclerc MH, Delahousse B, et al. Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY216). Semin Thromb Hemost. 1985;11:326-329.
13. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaron (Org 10172). Thromb Haemost. 1993; 70:554-561.
14. Greinacher A, Janssens U, Berg G, et al, for the Heparin-Associated Thrombocytopenia Study (HAT) investigators. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation. 1999;100:587-593.
15. Warkentin TE, Elavathil LJ, Hayward CPM, et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med. 1997;127:804-812.
16. Amiral J, Bridey F, Wolf M, et al. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb Haemost. 1995;73:21-28.
17. Song X, Huhle G, Wang L, et al. Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin. Circulation. 1999;100:1528-1532.
18. Hursting MJ, Alford KL, Becker JCP, et al. NOVASTAN (brand of argatroban): a small-molecule, direct thrombin inhibitor. Semin Thromb Hemost. 1997;23:503-516.
19. Walls JT, Curtis JJ, Silver D, et al. Heparin-induced thrombocytopenia in open heart surgical patients: sequelae of late recognition. Ann Thorac Surg. 1992;53:787-791.
20. Kraemer HC, Thiemann S. How Many Subjects? Statistical Power Analysis in Research. Newberry Park, Calif: Sage Publishing; 1987.
21. Pfueller SL, David R. Different platelet specificities of heparin-dependent platelet aggregating factors in heparin-associated immune thrombocytopenia. Br J Haematol. 1986;64:149 -159.
22. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood. 1986;67:27-30.
23. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy. 2000;20:318-329.
24. Hantgan RR, Jerome WG, Hursting MJ. No effect of clot age or thrombolysis on argatroban's inhibition of thrombin. Blood. 1998;92: 2064-2074.
25. Walenga JM, Koza MJ, Lewis BE, et al. Relative heparin-induced thrombocytopenic potential of low molecular weight heparins and new anti-thrombotic agents. Clin Appl Thromb Hemost. 1996;2(suppl 1):S21-S27.